Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder
July 18, 2022 09:25 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., July 18, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Provides Letter to Shareholders From CEO William Stilley
June 28, 2022 11:49 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., June 28, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today issued the following letter to its shareholders from the...
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical Trial
June 27, 2022 09:16 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., June 27, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence
June 14, 2022 10:48 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., June 14, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH
May 19, 2022 09:25 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., May 19, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on...
Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
May 16, 2022 09:25 ET
|
Adial Pharmaceuticals, Inc
Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current quarter Ended first quarter with cash and cash...
Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders
May 04, 2022 09:15 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on...
Adial Pharmaceuticals CEO to Participate in a Fireside Chat at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th
March 22, 2022 09:15 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., March 22, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
February 24, 2022 09:15 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Announces Closing of $10 Million Financing
February 16, 2022 09:26 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...